Evidence map›Paper›PMID 25901023›Full record

ArticleJournal of diabetes science and technology2015

Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion.

Howard Zisser, Eyal Dassau, Justin J Lee, Rebecca A Harvey, Wendy Bevier, Francis J Doyle

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01874392 (Feasibility Study Using Zone-MPC Controller), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01874392 nacompletednot on this map

Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) and Technosphere® Insulin Inhalation System From MannnKind Corp.

TypeinterventionalSponsorSansum Diabetes Research InstituteRan2012 to 2013Enrolled9ConditionsType 1 Diabetes MellitusArmsInvestigational inhaled insulin (Technosphere), Artificial Pancreas (AP) device (APS©)
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Early Stages of Automated Insulin Delivery.Journal of diabetes science and technology · 2025
    Review
  6. Early Stages of Automated Insulin Delivery.Diabetes technology & therapeutics · 2025
    Review
  7. Article
  8. Inhaled Insulin: Dead Horse or Rising Phoenix?Journal of diabetes science and technology · 2018
    Article
  9. Article
  10. Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.Journal of diabetes science and technology · 2017
    Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Howard ZisserSansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA hzisser@gmail.com.
Eyal DassauSansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Institute for Collaborative Biotechnologies, University of California, Santa Barbara, Santa Barbara, CA, USA.
Justin J LeeSansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA.
Rebecca A HarveySansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA.
Wendy BevierSansum Diabetes Research Institute, Santa Barbara, CA, USA.
Francis J DoyleSansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Institute for Collaborative Biotechnologies, University of California, Santa Barbara, Santa Barbara, CA, USA.
Sansum Diabetes Research Institute · USUniversity of California, Santa Barbara · US

Funding

Ambulatory Artificial Pancreas: merging physiology, behavior, and control designDP3DK094331 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI BASU, ANANDA, DOYLE, FRANCIS J · 2011 to 2014
$4.6M
Closed-loop Artificial Pancreas: Algorithm Engineering and Clinical EvaluationR01DK085628 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI DOYLE, FRANCIS J, JOVANOVIC, LOIS · 2009 to 2013
$3.4M
NIDDK NIH HHS DP3 DK094331NIDDK NIH HHS R01 DK085628NIDDK NIH HHS R01DK085628
6 · The paper itself

Abstract

objectiveThe purpose of this study was to investigate whether or not adding a fixed preprandial dose of inhaled insulin to a fully automated closed loop artificial pancreas would improve the postprandial glucose control without adding an increased risk of hypoglycemia. RESEARCH DESIGN AND

methodsNine subjects with T1DM were recruited for the study. The patients were on closed-loop control for 24 hours starting around 4:30 pm. Mixed meals (~50 g CHO) were given at 6:30 pm and 7:00 am the following day. For the treatment group each meal was preceded by the inhalation of one 10 U dose of Technosphere Insulin (TI). Subcutaneous insulin delivery was controlled by a zone model predictive control algorithm (zone-MPC). At 11:00 am, the patient exercised for 30 ± 5 minutes at 50% of predicted heart rate reserve.

resultsThe use of TI resulted in increasing the median percentage time in range (70-180 mg/dl, BG) during the 5-hour postprandial period by 21.6% (81.6% and 60% in the with/without TI cases, respectively, P = .06) and reducing the median postprandial glucose peak by 33 mg/dl (172 mg/dl and 205 mg/dl in the with and without TI cases, respectively, P = .004). The median percentage time in range 80-140 mg/dl during the entire study period was 67.5% as compared to percentage time in range without the use of TI of 55.2% (P = .03).

conclusionsAdding preprandial TI (See video supplement) to an automated closed-loop AP system resulted in superior postprandial control as demonstrated by lower postprandial glucose exposure without addition hypoglycemia.

Indexed as

Pancreas, ArtificialAdultBlood GlucoseDiabetes Mellitus, Type 1EatingEndpoint DeterminationFemaleFollow-Up StudiesHeart RateHumansHyperglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulinMaleMiddle AgedBlood GlucoseHypoglycemic AgentsInsulinartificial pancreasclosed-loopglucose controlHealth Monitoring Systemhypoglycemia mitigationinhaled insulintelemedicinetype 1 diabetesunannounced mealszone-MPC

Identifiers

PMID25901023
PMCPMC4604530
OpenAlexW2131733246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.